Cidara Therapeutics Inc (NASDAQ:CDTX) shares, rose in value on Thursday, April 25, with the stock price up by 5.53% to the previous day’s close as strong demand from buyers drove the stock to $12.97.
Actively observing the price movement in the recent trading, the stock is buoying the session at $12.29. Referring to stock’s 52-week performance, its high was $29.60, and the low was $10.00. On the whole, CDTX has fluctuated by -12.36% over the past month.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 24.34M, with a low estimate of 11.3M and a high estimate of 14.5M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 12.9M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CDTX’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of CDTX currently trading nearly -23.48% and -15.00% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 42.08, while the 7-day volatility ratio is showing 16.75% which for the 30-day chart, stands at 16.96%. Furthermore, Cidara Therapeutics Inc (CDTX)’s beta value is 1.09, and its average true range (ATR) is 2.25.
A comparison of Cidara Therapeutics Inc (CDTX) with its peers suggests the former has fared considerably weaker in the market. CDTX showed an intraday change of 5.53% in today’s session so far, and over the past year, it shrunk by -37.04%%.
Data on historical trading for Cidara Therapeutics Inc (NASDAQ:CDTX) indicates that the trading volumes over the past 3 months, they’ve averaged 43.78K. According to company’s latest data on outstanding shares, there are 91.23 million shares outstanding.
Nearly 9.96% of Cidara Therapeutics Inc’s shares belong to company insiders and institutional investors own 29.51% of the company’s shares. The stock has fallen by -18.32% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CDTX stock heading into the next quarter.
